As the herein targeted antigen EGFR is present in practically all squamous cell and some other cancers occurring in the clinic, the bispidine‐based selective and highly specific antibody fragments labelled with 64CuII hold a promise to deliver important therapy planning and monitoring options for head and neck, oesophageal, gastric, bladder and other mucosal cancer patients. The gene discussed is EGFR; the disease is cancer.